Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1127992 | 0.98 | GLA (0.75) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| SCHEMBL1194005 | 0.98 | GLA (0.69) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| SCHEMBL30489760 | 0.98 | GLA (0.69) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| SCHEMBL9150763 | 0.98 | GLA (0.69) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL30684598 | 0.96 | GLA (0.72) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| SCHEMBL465026 | 0.94 | GLA (0.74) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL1127696 | 0.92 | GLA (0.78) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| Bromide SCHEMBL11739950 | 0.92 | GLA (0.71) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL31326516 | 0.88 | GLA (0.57) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 | |
| SCHEMBL30489742 | 0.88 | GLA (0.57) | GLASMN1; SMN2CYP1A2MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3284467-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| WO-2018152554-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2018-08-23 | — | — | WO | claimed |
| EP-3284467-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2566476-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-20170326138-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2017-11-16 | — | — | US | claimed |
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| CN-105188675-A | Modified docetaxel liposome formulations | MALLINCKRODT LLC | 2015-12-23 | — | — | CN | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| EP-2566476-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023119762-A1 | METHOD FOR PRODUCING POLYMER DISPERSION FOR SOLID ELECTROLYTIC CAPACITOR, AND METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR | 株式会社レゾナック | 2023-06-29 | — | — | WO | disclosed |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | POVIVA CORP | 2023-03-30 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| CN-1205030-A | Machining fluid composition and method of machining | CINCINNATI MILACRON INC (US) | 1999-01-13 | — | — | CN | disclosed |
| WO-1997031921-A1 | IMMUNOSUPPRESSIVE COMPOUNDS AND METHODS | PHARMAGENESIS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031920-A1 | IMMUNOSUPPRESSIVE COMPOUNDS AND METHODS | PHARMAGENESIS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| US-5663335-A | ANTIINFLAMMATORY AGENTS; TREATMENT OF RHEUMATOID ARTHRITIS | PHARMAGENESIS, INC. (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | GLA 3707/4885SMN1; SMN2 3043/4885CYP1A2 4586/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | GLA 734/4885SMN1; SMN2 577/4885CYP1A2 1507/4885 |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | PNLIP, LIPA, SGMS2 | GLA 1093/4885SMN1; SMN2 3209/4885CYP1A2 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.